Filing Details
- Accession Number:
- 0001144204-16-119909
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2016-08-17 07:47:38
- Reporting Period:
- 2016-08-15
- Filing Date:
- 2016-08-17
- Accepted Time:
- 2016-08-17 07:47:38
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1369868 | China Biologic Products Inc. | CBPO | Biological Products, (No Disgnostic Substances) (2836) | 752308816 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1555364 | Ming Yang | 18Th Floor, Jialong I Nternational Building, 19 Chaoyang Park Road Beijing F4 100125 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2016-08-15 | 21,092 | $124.32 | 24,782 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct |
Footnotes
- Represents 21,092 shares of common stock (the "Sold Common Stock") sold on the open market at a weighted average price of $124.32 per share on August 15, 2016. The Reporting Person intends to use a portion of the proceeds from the sales of the Sold Common Stock to pay income tax due in connection with the scheduled vesting of certain restricted stock held by the Reporting Person.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in the open market at prices ranging from $124.00 to $125.13, inclusive. The Reporting Person undertakes to provide to any security holders of the Issuer or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this Footnote 2.